• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Categorical Exclusion under 21 CFR 25.31 (c) - Rotarix

Memorandum

Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
Division of Manufacturing and Product Quality

To:STN BL 125265/0
From:Jonathan McInnis, HFM-676
Subject:Categorical exclusion under 21 CFR 25.31 (c)
Date::March 21, 2008

I have reviewed pertinent sections of the Biologics License Application Supplement (STN number 125265/0) from GlaxoSmith Kline Biologicals, for the manufacture of rotavirus vaccine and find that their request for a categorical exclusion from an environmental assessment under 21 CFR 25.31 (c) is justified as the product consists of components already present in the environment.

Concurrence:

___________________________________________________
John A. Eltermann, Jr., R.Ph.,M.S.                                 Date
Director
Division of Manufacturing Product Quality

 

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002